JAZZ PHARMACEUTICALS PLC (JAZZ) Fundamental Analysis & Valuation

NASDAQ:JAZZ • IE00B4Q5ZN47

Current stock price

181.37 USD
-0.65 (-0.36%)
At close:
181 USD
-0.37 (-0.2%)
After Hours:

This JAZZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. JAZZ Profitability Analysis

1.1 Basic Checks

  • JAZZ had positive earnings in the past year.
  • In the past year JAZZ had a positive cash flow from operations.
  • In multiple years JAZZ reported negative net income over the last 5 years.
  • JAZZ had a positive operating cash flow in 4 of the past 5 years.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

  • The Return On Assets of JAZZ (-3.24%) is better than 74.48% of its industry peers.
  • Looking at the Return On Equity, with a value of -9.31%, JAZZ is in the better half of the industry, outperforming 75.52% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 3.95%, JAZZ belongs to the top of the industry, outperforming 81.77% of the companies in the same industry.
  • JAZZ had an Average Return On Invested Capital over the past 3 years of 3.85%. This is significantly below the industry average of 12.98%.
  • The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(3.95%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROIC 3.95%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

  • In the last couple of years the Profit Margin of JAZZ has declined.
  • JAZZ has a better Operating Margin (10.92%) than 83.33% of its industry peers.
  • JAZZ's Operating Margin has declined in the last couple of years.
  • JAZZ has a better Gross Margin (88.49%) than 92.19% of its industry peers.
  • JAZZ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.92%
PM (TTM) N/A
GM 88.49%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. JAZZ Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), JAZZ is destroying value.
  • There is no outstanding debt for JAZZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • JAZZ has an Altman-Z score of 1.61. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
  • JAZZ's Altman-Z score of 1.61 is in line compared to the rest of the industry. JAZZ outperforms 59.90% of its industry peers.
  • The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of JAZZ (4.33) is better than 84.90% of its industry peers.
  • JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.09, JAZZ is not doing good in the industry: 72.40% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Altman-Z 1.61
ROIC/WACC0.5
WACC7.92%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

  • JAZZ has a Current Ratio of 1.65. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of JAZZ (1.65) is worse than 66.15% of its industry peers.
  • JAZZ has a Quick Ratio of 1.44. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
  • JAZZ's Quick ratio of 1.44 is on the low side compared to the rest of the industry. JAZZ is outperformed by 64.06% of its industry peers.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.44
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. JAZZ Growth Analysis

3.1 Past

  • JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.30%.
  • JAZZ shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -8.04% yearly.
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.09%

3.2 Future

  • JAZZ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.81% yearly.
  • JAZZ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.16% yearly.
EPS Next Y204.02%
EPS Next 2Y75.53%
EPS Next 3Y49.05%
EPS Next 5Y31.81%
Revenue Next Year4.81%
Revenue Next 2Y6.23%
Revenue Next 3Y7.11%
Revenue Next 5Y7.16%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

8

4. JAZZ Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 22.12, the valuation of JAZZ can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 80.73% of the companies listed in the same industry.
  • JAZZ is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.11, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 7.28 indicates a rather cheap valuation of JAZZ.
  • JAZZ's Price/Forward Earnings ratio is rather cheap when compared to the industry. JAZZ is cheaper than 92.19% of the companies in the same industry.
  • JAZZ's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.12.
Industry RankSector Rank
PE 22.12
Fwd PE 7.28
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 84.38% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 91.15% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.01
EV/EBITDA 12.08
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of JAZZ may justify a higher PE ratio.
  • JAZZ's earnings are expected to grow with 49.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y75.53%
EPS Next 3Y49.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JAZZ Dividend Analysis

5.1 Amount

  • JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAZZ Fundamentals: All Metrics, Ratios and Statistics

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (3/17/2026, 8:25:18 PM)

After market: 181 -0.37 (-0.2%)

181.37

-0.65 (-0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners102.46%
Inst Owner Change0.47%
Ins Owners2.49%
Ins Owner Change2.03%
Market Cap11.17B
Revenue(TTM)N/A
Net Income(TTM)-368.48M
Analysts85.22
Price Target223.78 (23.38%)
Short Float %10.09%
Short Ratio5.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)0.88%
PT rev (3m)5.47%
EPS NQ rev (1m)-0.21%
EPS NQ rev (3m)1.53%
EPS NY rev (1m)0.44%
EPS NY rev (3m)1.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.02%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.23%
Valuation
Industry RankSector Rank
PE 22.12
Fwd PE 7.28
P/S 2.69
P/FCF 9.01
P/OCF 8.02
P/B 2.82
P/tB N/A
EV/EBITDA 12.08
EPS(TTM)8.2
EY4.52%
EPS(NY)24.93
Fwd EY13.75%
FCF(TTM)20.13
FCFY11.1%
OCF(TTM)22.61
OCFY12.47%
SpS67.54
BVpS64.31
TBVpS-39.54
PEG (NY)0.11
PEG (5Y)N/A
Graham Number108.93
Profitability
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROCE 5%
ROIC 3.95%
ROICexc 5.1%
ROICexgc 55.75%
OM 10.92%
PM (TTM) N/A
GM 88.49%
FCFM 29.8%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Debt/EBITDA 3.8
Cap/Depr 22.29%
Cap/Sales 3.68%
Interest Coverage 250
Cash Conversion 122.16%
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.44
Altman-Z 1.61
F-Score5
WACC7.92%
ROIC/WACC0.5
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
EPS Next Y204.02%
EPS Next 2Y75.53%
EPS Next 3Y49.05%
EPS Next 5Y31.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.09%
Revenue Next Year4.81%
Revenue Next 2Y6.23%
Revenue Next 3Y7.11%
Revenue Next 5Y7.16%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-57.5%
EBIT Next 3Y6.55%
EBIT Next 5Y7.24%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%

JAZZ PHARMACEUTICALS PLC / JAZZ Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.


Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 8 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.


Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.


Can you provide the financial health for JAZZ stock?

The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.


What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to grow by 204.02% in the next year.